Open AccessSafety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications
Author(s) -
Merav HeshinBekenstein,
Amit Ziv,
Nataša Toplak,
David Hagin,
Danielle Kadishevich,
Yonatan Butbul,
Esther Saiag,
Alla Kaufman,
Gabi Shefer,
Orli Sharon,
Sara Pel,
Ori Elkayam,
Yosef Uziel
Publication year - 2022
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keac103
Subject(s) - medicine , immunogenicity , vaccination , systemic lupus erythematosus , adverse effect , immunology , antibody , disease , arthritis
Adolescents with juvenile-onset autoimmune inflammatory rheumatic diseases (AIIRDs) could be at risk for disease flare secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or to withholding anti-inflammatory therapy. While vaccination can protect against coronavirus disease 2019 (COVID-19), safety and immunogenicity data regarding anti-SARS-CoV-2 vaccines among adolescents with AIIRDs are limited. This international, prospective, multicentre study evaluated the safety and immunogenicity of the BNT162b2 anti-SARS-CoV-2 vaccine among adolescents and young adults with juvenile-onset AIIRDs, 80% of whom are on chronic immunomodulatory therapy.